Rice Hall James & Associates LLC Boosts Stake in Amphastar Pharmaceuticals, Inc. $AMPH

Rice Hall James & Associates LLC boosted its stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 54.6% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 187,348 shares of the company’s stock after purchasing an additional 66,172 shares during the period. Rice Hall James & Associates LLC’s holdings in Amphastar Pharmaceuticals were worth $3,670,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMPH. AQR Capital Management LLC boosted its position in shares of Amphastar Pharmaceuticals by 82.0% during the first quarter. AQR Capital Management LLC now owns 53,638 shares of the company’s stock worth $1,555,000 after buying an additional 24,167 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Amphastar Pharmaceuticals by 2.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,489 shares of the company’s stock valued at $652,000 after buying an additional 613 shares during the period. Intech Investment Management LLC raised its holdings in shares of Amphastar Pharmaceuticals by 43.0% in the 1st quarter. Intech Investment Management LLC now owns 60,289 shares of the company’s stock valued at $1,748,000 after buying an additional 18,133 shares during the period. Arrowstreet Capital Limited Partnership acquired a new position in Amphastar Pharmaceuticals during the 2nd quarter worth about $1,865,000. Finally, Invesco Ltd. lifted its stake in Amphastar Pharmaceuticals by 7.7% during the 2nd quarter. Invesco Ltd. now owns 386,971 shares of the company’s stock worth $8,885,000 after acquiring an additional 27,828 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Stock Performance

NASDAQ:AMPH opened at $18.72 on Monday. The firm has a market cap of $825.36 million, a PE ratio of 11.28, a price-to-earnings-growth ratio of 3.68 and a beta of 0.89. The stock has a fifty day moving average price of $19.32 and a 200 day moving average price of $21.88. Amphastar Pharmaceuticals, Inc. has a 12-month low of $16.65 and a 12-month high of $31.26. The company has a current ratio of 3.85, a quick ratio of 2.82 and a debt-to-equity ratio of 0.79.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last issued its quarterly earnings results on Thursday, May 7th. The company reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.70 by ($0.28). The company had revenue of $171.17 million for the quarter, compared to analysts’ expectations of $173.46 million. Amphastar Pharmaceuticals had a return on equity of 15.12% and a net margin of 11.00%. Sell-side analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 2.41 earnings per share for the current fiscal year.

Analysts Set New Price Targets

AMPH has been the subject of a number of research analyst reports. Bank of America restated an “underperform” rating and set a $20.00 target price (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, June 29th. Piper Sandler reissued a “neutral” rating and set a $21.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a research report on Monday, May 11th. Wells Fargo & Company reissued an “equal weight” rating and issued a $19.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a research note on Thursday, May 14th. Jefferies Financial Group restated a “hold” rating and issued a $22.00 price objective (down from $30.00) on shares of Amphastar Pharmaceuticals in a report on Tuesday, April 21st. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Friday, May 8th. Six equities research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Amphastar Pharmaceuticals has an average rating of “Reduce” and a consensus target price of $22.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.